Comparative bioavailability study of a new formulation of injection of 75 mg diclofenac sodium in 1 mL with the conventional injection of 75 mg diclofenac sodium given in 3 mL volume

Current Clinical Pharmacology

Volumn 6, Issue 1, 2011, Pages 26-29

  Shep, Dhaneshwar ^a   Ojha, Ashwini ^b   Patel, Sweta ^b   Nivsarkar, Manish ^b   Jaiswal, Vijaya ^a   Padh, Harish ^c,d  

^a Troikaa Pharmaceuticals Ltd   (India)

^b B V PATEL PHARMACEUTICAL EDUCATION AND RESEARCH DEVELOPMENT PERD CENTRE   (India)

^c NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER AHMEDABAD   (India)

^d SARDAR PATEL UNIVERSITY   (India)

Author keywords

Bioavailability; Diclofenac sodium; Injection; Intragluteal; Pharmacokinetics; Volume

Indexed keywords

DICLOFENAC; DYNAPAR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BLOOD ANALYSIS; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DICLOFENAC; EXCIPIENTS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; PROPYLENE GLYCOL; THERAPEUTIC EQUIVALENCY;

EID: 79953056202     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411794941359     Document Type: Article

References (12)

1. th ed. McGraw-Hill: New York 2001.
2. Novartis New Zealand Limited. Voltaren (Diclofenac Sodium) 75 mg/3mL Solution for Injection prescribing information: Auckland; 2010.
3. Doenicke A, Nebauer AE, Hoernecke R, Mayer M, Roizen MF. Osmolalities of propylene glycol-containing drug formulations for parenteral use. Should propylene glycol be used as a solvent? Anesth Analg 1992; 75(3): 431-5.
4. Chaudhari LS, Patel RD, Shroff P, Wagh H, Vaidya SV, Shubha Rani. A randomized comparative double blind study comparing pain at the site of injection diclofenac sodium versus injection diclofenac sodium propylene glycol free (Dynapar AQ) given intragluteally. JAMA 2004; 3(9): 71-3.
5. Ojha A, Shep D, Nivsarkar M, Patel S, Jaiswal V, Padh H. Pharmacokinetic profile of a new formulation of injection diclofenac designed for intradeltoid use. Expert Opin Pharmacother 2009; 10(4): 517-22.
6. Kurowski M. Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug. Z Rheumatol 1988; 47(1): 37-42.
7. Rakhshanda Nawaz, Muhammad Nawaz, Asma Butt, M. Zafar Ullah Saleemi. Kinetics of diclofenac sodium; single oral dose disposition in male volunteers. Professional 2004; 11(4): 411-6.
8. Antonio Marzo, Valentina Reiner. Open questions on bioequivalence: the case of multiple peak phenomenon. JPP 2004; 56: 281-2.
9. Terhaag B, Hoffmann A, Barkworth M, Vens-Cappell B. Bioavailability of a new effervescent tablet of diclofenac. Int J Clin Pharmacol Ther 2000; 38(11): 546-51.
10. Macía MA, Frias J, Carcas AJ, Guerra P, Valiente R, Lucero ML. Comparative bioavailability of a dispersible formulation of diclofenac and finding of double plasma peaks. Int J Clin Pharmacol Ther 1995; 33(6): 333-9.
11. Bettini, R, Giordano F, Donini C, Massimo G, Castellani PL, Colombo P. Swelling force development as a result of hydrate formation in diclofenac sodium or nitrofurantoin tablets. S T P Pharm Sci 2000; 10: 335-9.
12. Subnis BM, Patel P, Pradhan CV, Kakar PN, Varma K, Jaiswal V. Evaluation of the effectiveness and safety of a new formulation of Injection Diclofenac DYNAPAR AQ (75 mg/mL) in the management of post operative pain: A pilot study. Indian Med Gazette 2010; 6: 213-7.